GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 229 filers reported holding GENMAB A/S in Q3 2023. The put-call ratio across all filers is 1.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,350,982 | -37.6% | 38,304 | -33.2% | 0.00% | -20.0% |
| Q1 2023 | $2,163,988 | -11.9% | 57,309 | -1.1% | 0.01% | 0.0% |
| Q4 2022 | $2,455,158 | +8.3% | 57,932 | -17.9% | 0.01% | -16.7% |
| Q3 2022 | $2,268,000 | -5.3% | 70,579 | -4.3% | 0.01% | 0.0% |
| Q2 2022 | $2,396,000 | +10.4% | 73,746 | +22.9% | 0.01% | +20.0% |
| Q1 2022 | $2,170,000 | +1.2% | 59,988 | +10.6% | 0.01% | 0.0% |
| Q4 2021 | $2,145,000 | -8.4% | 54,230 | +1.2% | 0.01% | -16.7% |
| Q3 2021 | $2,341,000 | +12.1% | 53,575 | +4.7% | 0.01% | +20.0% |
| Q2 2021 | $2,089,000 | +46.7% | 51,154 | +17.9% | 0.01% | 0.0% |
| Q1 2021 | $1,424,000 | -23.5% | 43,372 | -5.2% | 0.01% | -16.7% |
| Q4 2020 | $1,861,000 | +24.1% | 45,763 | +11.7% | 0.01% | 0.0% |
| Q3 2020 | $1,499,000 | +254.4% | 40,953 | +228.3% | 0.01% | +200.0% |
| Q2 2020 | $423,000 | +43.9% | 12,473 | -10.1% | 0.00% | 0.0% |
| Q1 2020 | $294,000 | – | 13,873 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 52,148 | $1,839,260 | 1.67% |
| Ativo Capital Management LLC | 28,442 | $1,003,132 | 1.13% |
| HARDING LOEVNER LP | 3,204,230 | $113,013,183 | 0.75% |
| Hardman Johnston Global Advisors LLC | 592,318 | $20,891,056 | 0.70% |
| Yorktown Management & Research Co Inc | 16,600 | $585,482 | 0.66% |
| TORRAY INVESTMENT PARTNERS LLC | 104,516 | $3,686,279 | 0.65% |
| First Light Asset Management, LLC | 157,147 | $5,542,575 | 0.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,300 | $1,561,575 | 0.53% |
| Capricorn Fund Managers Ltd | 37,007 | $1,305,237 | 0.45% |
| Legacy Wealth Asset Management, LLC | 29,496 | $1,040,324 | 0.38% |